The FDA will use a range of Emulate's Organ-Chips technology to study the safety, efficacy, and mechanisms of drugs regulated by the FDA. Initial studies will recreate the natural physiology of specific human tissues and organs in areas where conventional cell culture and animal-based testing methods have limitations, such as Alzheimer's disease and COVID-19.

The Lung-Chip study, led by the FDA's Center for Biologics Evaluation and Research, will explore why individuals experience a wide spectrum of disease severity and what constitutes a real protection against future SARS-CoV-2 infection.

This agreement follows the completion of an initial collaboration in 2018 that focused on toxicity studies using the company's Liver-Chip product.

PHC, On-chip Biotech partner on cell culture applications
PHC and On-chip Biotechnologies are partnering to deliver total cell culturing solutions for researchers and organizations across a wide range of applications.

Javelin, Pfizer to develop organ-on-a-chip platform
Javelin Biotech has entered a three-year collaboration with Pfizer to design and build a platform to evaluate absorption, distribution, metabolism, and...

Consortium studies body-on-a-chip technology
The Wake Forest Institute for Regenerative Medicine and Oracle Health Sciences have joined forces to develop a consortium of industry, government, and...

Accelerating COVID-19 drug repurposing with computers, organ chips
The U.S. Defense Advanced Research Projects Agency (DARPA) has awarded the Wyss Institute for Biologically Inspired Engineering at Harvard University...